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Abstract
Background: The tumour suppressor phosphatase and tensin homolog (PTEN) is an important
negative regulator of cell-survival signaling. To evaluate the correlation between PTEN expression
and clinicopathological characteristics of colorectal cancer patients with and without liver
metastases, we investigated PTEN expression in primary colorectal cancer and colorectal cancer
liver metastases.
Methods:  Sixty-nine pairs of primary colorectal cancer and corresponding liver metastasis
specimens were analyzed immunohistochemically, and the correlation between
immunohistochemical findings and clinicopathological factors was investigated. Seventy primary
colorectal cancer specimens from patients without liver metastases were used as controls.
Results: PTEN was strongly expressed in 44 (62.9%) colorectal cancer specimens from patients
without liver metastases. In contrast, PTEN was weakly expressed in 52 (75.4%) primary colorectal
cancer specimens from patients with liver metastases, and was absent in liver metastases. Weak
PTEN expression in colorectal cancer tissues was significantly associated with advanced TNM stage
(p < 0.01) and lymph node metastasis (p < 0.05). PTEN expression was significantly stronger in
primary colorectal cancer specimens from patients without liver metastases. Furthermore, among
colorectal cancer patients with liver metastases, the 5-year survival rate was significantly higher in
patients with positive PTEN expression compared to those with negative PTEN expression (p =
0.012).
Conclusion: Our results suggest that loss of PTEN expression is involved with colorectal cancer
aggressive capacity and that diagnostic evaluation of PTEN expression may provide valuable
prognostic information to aid treatment strategies for colorectal cancer patients.
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Background
Colorectal cancer is the fourth most common malignancy
and the second leading cause of cancer death in Western
countries, with liver metastases being the primary cause of
death in most patients [1]. Despite improved cancer
screening methods and adjuvant treatment regimens for
primary colorectal cancer, synchronous and meta-
chronous liver metastases remain a critical problem [2,3].
Approximately 40% of patients who develop metastatic
disease have tumour(s) confined to the liver, which has
driven interest in regional therapies that target the liver
[4].
An essential process for promotion of metastasis is cancer
cell invasion, which is controlled by several biological fac-
tors, most notably tumour proliferation and invasion. The
tumour suppressor phosphatase and tensin homolog
(PTEN) is a critical negative regulator of the cell-survival
signaling pathway initiated by phosphatidylinositol 3-
kinase (PI3K) [5-9]. The PI3K-PTEN pathway promotes
cell survival and proliferation, increases in cell size, and
chemoresistance. Each of these biological outcomes
results from the interaction of this pathway with other sig-
naling networks. Further, loss of PTEN expression has
been reported to be strongly associated with aggressive
tumour features [10-13].
Controlling liver metastasis is considered essential in the
treatment of colorectal cancer. It is therefore reasonable to
expect that evaluation of PTEN expression levels in pri-
mary colorectal cancer and in liver metastases may pro-
vide information that will allow better prediction of
therapy benefit. The aims of this study were to investigate
PTEN expression in primary colorectal cancer and in
colorectal cancer liver metastases and to evaluate the cor-
relation between PTEN expression and clinicopathologi-
cal characteristics of colorectal cancer patients with and
without liver metastases. Our results suggest that loss of
PTEN expression is associated with the aggressive capacity
of colorectal cancer and that understanding the biologic
mechanisms responsible for regulation of PTEN expres-
sion may enable better translational treatment of colorec-
tal cancer patients.
Methods
Patients and tissue specimens
Sixty-nine pairs of primary colorectal cancer and corre-
sponding liver metastasis specimens were analyzed in this
study. Seventy primary colorectal cancer specimens from
patients without liver metastasis were used as controls. All
tissues were obtained in the Department of Gastroentero-
logical Surgery, Nagoya City University Hospital with
informed consent from patients or their relatives. Tissue
samples were fixed in 10% formalin and subsequently
embedded in paraffin.
Immunohistochemistry
Resected colorectal cancer and paired liver metastasis tis-
sue specimens were sliced into 3.5-μm-thick sections and
deparaffinized in five min. After blocking nonspecific
binding with 10% bovine serum (Wako, Osaka, Japan),
sections were incubated with anti-PTEN antibodies (clone
28H6; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at
1:300 dilution for 60 min at room temperature. Immuno-
histochemical staining was performed using the peroxi-
dase-based EnVision™ kit (DakoCytomation,
Copenhagen, Denmark) according to the manufacturer's
instructions. Negative control sections were prepared
using normal mouse IgG instead of primary antibody.
Immunohistochemical evaluation
Two observers (H.Ta. and H.S.) independently evaluated
the immunohistochemical staining results. The concord-
ance ratio was >90%. Differences of opinion were
resolved by reaching a consensus with the assistance of a
third evaluator (H.Tb.). The intensity of tissue staining was
graded semiquantitatively on a 4-point scale (-, +, ++, and
+++). Likewise, the proportion of cells stained was
assessed on a 4-point scale (1, 0–15%; 2, 15–50%; 3, 50–
85%; 4, 85–100% cells stained). Tissues were classified
into strongly staining (Group S) and weakly staining
(Group W) groups according to the intensity and propor-
tion of immunohistochemical staining. Immunohisto-
chemical staining of intensity more than +++ or a staining
area > 3 was classified as Group S, the intensity less than
++ and a staining area < 2 was classified as Group W.
Statistical analysis
The Mann-Whitney U test was used to compare clinico-
pathological and immunohistochemical characteristics.
Differences between Kaplan-Meier survival curves based
on PTEN expression were tested with the Wilcoxon test.
Statistical significance was indicated by p < 0.05 or 0.01.
Data are presented as mean ± standard deviation (s.d.).
Results
Clinicopathological findings of patients with colorectal 
cancer with liver metastasis
Sixty-nine pairs of primary colorectal cancer and corre-
sponding liver metastasis specimens were evaluated
(Table 1). The mean age of all patients was 60.7 ± 9.9
years. pT, pN, and pM categories were determined accord-
ing to the TNM classification [14]. The M category was
determined from preoperative imaging findings, intraop-
erative findings, and postoperative imaging findings. A
total of 23 patients had synchronous liver metastases and
46 had metachronous metastases; 38 patients had solitary
liver metastases and 31 patients had multiple (≥ 2) metas-
tases. Some patients received postoperative treatment;
however, there was no difference in outcome between the
various treatment modalities. The median follow-up timeBMC Gastroenterology 2008, 8:56 http://www.biomedcentral.com/1471-230X/8/56
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for patients at the time of survival analysis was 35.5
months after primary surgery. The actuarial 5-year survival
rate of patients with colorectal cancer with liver metas-
tases was 34.3%.
Immunohistochemical localization of PTEN in colorectal 
cancer and liver metastasis specimens
PTEN expression was evaluated in primary colorectal can-
cer and corresponding liver metastasis specimens. PTEN
was strongly expressed in 44 (62.9%) colorectal cancer
specimens from patients without liver metastases (con-
trol, n = 70). In contrast, weak PTEN expression was
observed in 52 (75.4%) primary colorectal cancer speci-
mens from patients with liver metastases, and PTEN
expression was absent in liver metastasis cancer specimens
(Figure 1A–D). The marked nuclear staining of PTEN and
slight cytoplasmic staining were observed. Weak PTEN
expression was significantly associated with advanced
TNM stage and lymph node metastasis (Table 2). The
actuarial 5-year survival rate of patients with colorectal
cancer with liver metastases and positive PTEN expression
was 64.4%. In contrast, the actuarial 5-year survival rate of
patients with colorectal cancer with liver metastases and
negative PTEN expression was 12.7% (Figure 2). In addi-
tion, among colorectal cancer patients with liver metas-
tases, there was a significant difference in 5-year survival
rate between patients with positive PTEN expression and
those with negative PTEN expression (p = 0.012).
Discussion
PTEN is a potent tumour suppressor gene that is fre-
quently mutated in a large number of human cancers,
including brain, endometrial, prostate, and kidney cancer.
PTEN downregulates the activity of the lipid second mes-
senger phosphoinositol-3,4,5-triphosphate (PIP3)
through dephosphorylation, thereby negatively regulating
PI3K-triggered signaling. The PI3K/Akt pathway is an
important driver of cell proliferation and survival, most
notably in cells responding to growth factor receptor
engagement. Survival signals such as growth factors,
cytokines, and hormones are known to activate PI3K [15].
Subsequently, PI3K activates Akt/PKB, which interferes
with cellular apoptotic machinery [16]. Activated Akt/PKB
mediates cell survival via the regulation of numerous pro-
teins involved in apoptosis, such as the transcription fac-
tor NF-κB [17]. Akt-triggered survival signaling is
suppressed by PTEN antagonization of PI3K activity.
PI3K and Akt are overexpressed in a variety of cancers
[18,19], while PTEN is frequently deleted in advanced
tumours [20,21]. These alterations lead to constitutively
active survival signaling that enhances the insensitivity of
tumour cells to apoptosis induction. Via PI3K antago-
nism, PTEN functions as a tumour suppressor. Thus, the
PI3K-PTEN signaling network is crucial to proper regula-
tion of cell survival. By reducing PI3K activity, PTEN
inhibits the recruitment of Akt to the plasma membrane
and prevents its activation. PTEN function is regulated by
post-translational modification, cellular localization, and
redox modulation of its active-site cysteine [22,23]. When
PTEN is deleted, mutated, or otherwise inactivated, activa-
tion of PI3K effectors – particularly the key survival kinase
Akt/PKB – can occur in the absence of any exogenous
stimuli, allowing tumourigenesis to be initiated.
The molecular mechanisms by which PTEN controls stem
cell behavior are currently unknown. Previously, PTEN
loss has been reported to lead to an increase in self-
renewal and proliferation in neural stem cells [24], at least
in part, by modulating the G0 to G1 cell cycle transition, a
Table 1: Comparison of clinicopathological findings by existence of liver metastases
Patients with liver metastases n = 69 
(cases)
Patients without liver metastases n = 70 
(cases)
p value
Gender M/F 40/29 38/32 N.S.
Age Years 60.7 ± 9.9 62.5 ± 10.1 N.S.
TNM stage I/II/III/IV 0/12/23/34 11/38/21/0 < 0.01a
Tumour site C/R 45/24 49/21 N.S.
LN mets Yes/No 41/28 31/39 N.S.
Differentiation w/mod/por 37/30/2 21/33/16 N.S.
Liver mets Sync/Meta 23/46 N.A. N.A.
No. of liver mets Solo/Multi 38/31 N.A. N.A.
PTEN expression S/W 17/52 44/26 < 0.01a
Median follow-up Months 35.5 ± 27.4 37.2 ± 39.9 N.S.
5-year survival (%) 34.3 79.2 < 0.01b
LN, lymph node; mets, metastasis; M, male; F, female; C, colon; R, rectum; w, well differentiated adenocarcinoma; mod, moderately differentiated 
adenocarcinoma; por, poorly differentiated adenocarcinoma; Sync, synchronous metastasis; Meta, metachronous metastasis; Solo, solitary 
metastasis; Multi, multiple metastases; S, strong; W, weak; N.A., not applicable; N.S., not significant. The a p-values were obtained using the Mann-
Whiteny U test. The b p-values were obtained using Kaplan-Meier survival curves based on PTEN expression tested with the Wilcoxon test. Values 
of age are given mean ± s.d. N.S., not significant.BMC Gastroenterology 2008, 8:56 http://www.biomedcentral.com/1471-230X/8/56
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critical step for stem cell self-renewal and differentiation
[25]. Studies of mouse embryonic fibroblasts and B lym-
phocytes lacking the PTEN gene have demonstrated that
these cells migrate faster than their wild-type counterparts
in culture, indicating a physiological role for PTEN in the
suppression of cell motility [26,27]. Re-introduction of
PTEN into mammalian cells lacking the enzyme inhibits
the motility of several cell lineages, including mouse
embryo fibroblasts and tumour-derived cells of glial,
prostate, and T cell origin [25,27-30]; however, the major-
ity of these studies have not addressed the biologic mech-
anism of PTEN action.
Numerous tumour types, including sporadic tumours and
those that arise in association with a cancer predisposition
syndrome, demonstrate either absent or altered PTEN
expression [31]. Recent reports demonstrated the relation-
ship between PTEN expression and the efficacy of cetuxi-
mab, a chimeric IgG1 monoclonal antibody that targets
the extracellular domain of epidermal growth factor
receptor (EGFR) [32-34]. Frattini et al reported the loss of
PTEN expression is observed in 40 % of primary colorectal
cancer patients with synchronous or metachronous meta-
static lesion and the loss of PTEN protein expression is
associated with nonresponsiveness to cetuximab [32].
They also demonstrated a trend toward PTEN protein
reduction in mucinous colorectal cancers, compared with
well-differentiated tumors. In this study, we investigated
PTEN expression in primary colorectal cancer and in
colorectal cancer liver metastases and evaluated the corre-
Expression of PTEN in colon cancer specimens Figure 1
Expression of PTEN in colon cancer specimens. Immunohistochemistry was performed using a monoclonal anti-PTEN 
antibody (A, C) or negative control antibody (B) on a section sequential to that used in (A). (A) Strong PTEN expression in a 
representative moderately-differentiated adenocarcinoma specimen from colon cancer patients without associated liver metas-
tasis (×100). (C) Expression of PTEN is not observed in a representative moderately-differentiated adenocarcinoma specimen 
from colon cancer patients with liver metastasis (×100). (D) Expression of PTEN is not observed in a specimen from metastatic 
liver tumor, in contrast, PTEN expression is observed in normal liver tissue (×100).BMC Gastroenterology 2008, 8:56 http://www.biomedcentral.com/1471-230X/8/56
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Kaplan-Meier survival curves for colorectal cancer patients with liver metastases Figure 2
Kaplan-Meier survival curves for colorectal cancer patients with liver metastases. A comparison of survival curves 
between cases with (thick line) and without (broken line) strong PTEN expression.
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Table 2: Comparison of clinicopathological findings by PTEN expression
PTEN expression
Group S (n = 17) Group W (n = 52) p value
Gender M/F 10/7 30/22 N.S.
Age Year 60.3 ± 9.7 60.9 ± 10.1 N.S.
TNM stage I/II/III/IV 0/6/7/4 0/6/16/30 < 0.01a
Tumour site C/R 11/6 34/18 N.S.
LN mets Yes/No 8/9 39/13 < 0.05a
Differentiation w/mod/por 10/7/0 27/23/2 N.S.
Liver mets Sync/Meta 4/13 19/33 N.S.
No. of liver mets Solo/Multi 9/8 29/23 N.S.
5-year survival (%) 64.4 12.7 < 0.05b
LN, lymph node; mets, metastasis; M, male; F, female; C, colon; R, rectum; w, well differentiated adenocarcinoma; mod, moderately differentiated 
adenocarcinoma; por, poorly differentiated adenocarcinoma; Sync, synchronous metastasis; Meta, metachronous metastasis, Solo, solitary 
metastasis; Multi, multiple metastases; N.S., not significant. The ap-values were obtained using the Mann-Whiteny U test. The bp-values were 
obtained using Kaplan-Meier survival curves based on PTEN expression tested with the Wilcoxon test. Values of age are given mean ± s.d. N.S., not 
significant.BMC Gastroenterology 2008, 8:56 http://www.biomedcentral.com/1471-230X/8/56
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lation between PTEN expression and clinicopathological
characteristics of colorectal cancer patients with and with-
out liver metastases. In our immunohistochemical analy-
sis, strong PTEN expression was observed in 62.9% of
primary colorectal cancer specimens obtained from
patients without liver metastases, while weak PTEN
expression was observed in 75.4% of colorectal cancer
specimens obtained from patients with liver metastases.
In addition, among colorectal cancer patients with liver
metastases, we found that weak PTEN expression was sig-
nificantly associated with advanced TNM stage and lymph
node metastasis. Furthermore, among colorectal cancer
patients with liver metastases, a significant difference in 5-
year survival rate was observed between patients with pos-
itive PTEN expression and those with negative PTEN
expression. This is the first report to demonstrate an asso-
ciation between poor prognosis and PTEN expression in
colorectal cancer patients with liver metastases.
Conclusion
In this study, we found that weak PTEN expression is sig-
nificantly associated with advanced TNM stage and lymph
node metastasis. This is the first report to demonstrate a
significant difference in 5-year survival rate between
patients with positive PTEN expression and those with
negative PTEN expression among colorectal cancer
patients with liver metastases. These observations suggest
that diagnostic evaluation of PTEN expression might pro-
vide valuable prognostic information to aid treatment
strategies for colorectal cancer patients.
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